Practice of incentives for orphan drug research and development in the united states and enlightenment for China:based on the perspective of drug life cycleWU Jing-jing, YUAN Hui-qin, TIAN Meng-yan, LI Guo-dong, MAO Ning-ying2081-2087
Progress in the implementation of China's drug conditional approval system and some suggestionsLIU Xuan, LIN Lin, TIAN Li-juan2088-2095
Methods of indirect comparison of clinical treatments and case analysisLI Tong-xu, ZHANG Lu-wen, JIA Shuo-peng, HE Han-qing, WANG Xin, TANG Yu, LI Ning, HUANG Hui-yao2096-2101
The development trend analysis of glucagon-like peptide-1 receptor agonists from a patent perspectiveLIU Chun-jie, TONG Jing-yi2102-2108
Revelutamide,a second-generation androgen receptor antagonist for the treatment of metastatic hormone-sensitive prostate cancerCUI Ying-jie, ZHANG Gui-fang2109-2113
Safety evaluation of anti-tumor drugs during early clinical trialsHU Wen-juan, DU Yu, TANG Ling, YANG Zhi-min2114-2118
Research progress in cyclin-dependent kinase 9 inhibitorsCAO Zhi-hao, ZENG Yang-jie, LI Wen-xin, ZHANG Rui, WANG Ju-bo, REN Xiao-dong2119-2130
Progress in application of organoids technique in new drug evaluationWANG Jun-long, FU Li-xia, WANG Qing-yang, WANG Lei, ZHAO Dan-dan, TIAN Ru, LIU Li, CUI Yi-min2131-2137
Research progress in pain management and pharmacological treatment for lumbar facet joint osteoarthritisLIU Chi, SUN Chang-tai, WANG Xiao-bin, QIU Yu-dian, WANG Qiang2138-2142
Bioequivalence and safety of lopinavir-ritonavir tablets in healthy Chinese subjectsLIU Tian-mei, DU Xiao-lin, YONG Xiao-lan2143-2148